Application of serum marker in preparation of kit for evaluating curative effect of mesenchymal stem cells on Crohn disease
Serum metabolites in Crohn's disease mice were detected by using serum marker compositions of 4-agental, β-D-glucopyranonic acid and prolyl arginine isomer 1 and CIL LC-MS technology , solves the problem that the treatment effect of mesenchymal stem cells cannot be effectively evaluated in the prior art, screens out relevant biomarkers, and provides in-depth understanding of the metabolic changes in Crohn's disease and support for the therapeutic impact.
Patent Information
- Application Number
- CN202410886317.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-03
- Publication Date
- 2024-11-08
AI Technical Summary
Existing treatments for Crohn's disease cannot completely solve intestinal inflammation and tissue damage, and traditional therapies have side effects and long-term risks, and there is a lack of effective methods to evaluate the therapeutic effects of mesenchymal stem cells.
Serum marker composition composed of 4-agentaldehyde, β-D-glucopyranonic acid and prolyl arginine isomer 1 was used to detect serum of Crohn's disease mice with CIL LC-MS technology. Metabolites, screening out biomarkers related to mesenchymal stem cell therapy, and providing kits for evaluating the therapeutic effect of mesenchymal stem cell.
Successfully screened out serum metabolites related to the treatment of Crohn's disease, providing new potential markers, which helps to deeply understand the metabolic changes in Crohn's disease and the effects of mesenchymal stem cell therapy, for clinical Conversion provides data support.
Smart Images

Figure CN118910203A_ABST
Abstract
Description
Field of the Invention
[0001] The present invention belongs to the field of medical technology, and relates to the application of serum markers in preparing a kit for evaluating the efficacy of mesenchymal stem cells on Crohn's disease, and specifically relates to the application of 4-guanidine aldehyde, β-D-pyranoglucopyranose acid, and prolylarginine isomer 1 as serum markers for evaluating Crohn's disease. Background Art
[0002] Crohn's disease is a chronic inflammatory nonspecific intestinal disease with the main clinical manifestations of abdominal pain, diarrhea, abdominal mass, perianal lesions, etc. The lesions can affect the entire digestive tract. Because the etiology and specific pathogenesis of Crohn's disease are still unclear, there is currently no method to completely cure Crohn's disease. Inducing and maintaining clinical remission and mucosal healing, preventing and treating complications, strengthening long-term management of patients and improving patients' quality of life are the main measures in clinical practice. Although traditional treatments such as anti-inflammatory drugs and immunosuppressants can relieve patients' symptoms, they cannot completely solve the underlying intestinal inflammation and tissue damage, and may cause treatment side effects and long-term risks of the disease.
[0003] Mesenchymal stem cells are mainly found in connective tissue and organ stroma. They are a type of multipotent stem cells located in the mesoderm. They can differentiate into a variety of tissue cells under specific induction conditions in vivo or in vitro, and have the potential to promote regeneration and immunoregulation. Mesenchymal stem cells still have the potential for self-renewal and multidirectional differentiation after continuous subculture and cryopreservation, and have low immunogenicity. They can be introduced into the host through various routes without causing immune rejection reactions in the host, greatly reducing the probability of graft-versus-host disease. Placental-derived mesenchymal stem cells have the advantages of simple isolation methods, abundant sources, and no ethical restrictions, and have gradually become one of the advantageous cells for stem cell transplantation therapy. Utilizing the regenerative and immunoregulatory properties of cells, mesenchymal stem cells are expected to become a potential supplementary or alternative treatment strategy for Crohn's disease, especially for patients who do not respond well to traditional therapies. Summary of the invention
[0004] The first object of the present invention is to overcome the deficiencies in the prior art and provide an application of serum markers in the preparation of a product for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease.
[0005] The use of a serum marker in the preparation of a product for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease, wherein the serum marker adopts a composition consisting of at least 4-guanidine aldehyde, β-D-pyranoglucopyranose acid and prolyl arginine isomer 1; the chemical formula of the prolyl arginine isomer 1 is shown below:
[0006]
[0007] Preferably, the product comprises a test kit, a chip or a test paper.
[0008] Preferably, the kit uses serum as the detection sample.
[0009] Preferably, the chip comprises a solid phase carrier, and probes attached thereto that specifically recognize kynurenine and formyl-5-hydroxykynurenamine.
[0010] The second object of the present invention is to provide a kit for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease, wherein the kit comprises reagents for detecting 4-guanidine aldehyde, β-D-pyranoglucopyranose acid and prolyl arginine isomer 1.
[0011] The third object of the present invention is to use a reagent for detecting serum markers in the preparation of a product for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease, wherein the serum marker adopts a composition consisting of at least 4-guanidine aldehyde, β-D-pyranoglucopyranose acid and prolyl arginine isomer 1.
[0012] Preferably, the product comprises a test kit, a chip or a test paper.
[0013] To solve the technical problem, the present invention is achieved by combining CIL LC-MS technology to detect serum metabolites of Crohn's disease mice, comprising the following steps:
[0014] (1) Mesenchymal stem cell transplantation for the treatment of Crohn's disease in mice
[0015] In this invention, 200 μL phosphate buffered saline (PBS) was intraperitoneally injected into 24-week-old female SAMP1 / Yit mice as the model group, and 2×10 6 MSCs / 200 μL PBS was used as the treatment group, and AKR / J mice of the same age were intraperitoneally injected with 200 μL PBS as the normal control group; peripheral serum of mice was collected on the 0th, 3rd, 7th and 14th days of the experiment for later use;
[0016] (2) Extraction of serum metabolites
[0017] The collected serum was divided into two parts, one as an individual sample, and the other as a pooled sample by mixing the serum evenly; serum:methanol=1:3 (v / v) was mixed to extract metabolites in the serum; metabolites in the supernatant were collected by centrifugation and freeze-dried for later use;
[0018] (3) 12 C / 13 C-isotope labeled metabolites
[0019] After the freeze-dried metabolites were dissolved in pure water, acetonitrile and sodium carbonate / sodium bicarbonate buffer were added; 12 Independent serum samples were labeled with C-dansyl marker. 13 The mixed serum sample is labeled with a C-dansyl marker; finally, sodium hydroxide and formic acid / water solution are added to neutralize the reaction and prepare for quantification;
[0020] (4) Liquid chromatography-ultraviolet spectroscopy (LC-UV) quantification
[0021] In order to ensure the same total concentration of each sample during LC-MS analysis, the metabolites were quantitatively operated based on LC-UV technology, and the temperature, injection volume, composition and ratio of the mobile phase, and steepness of the elution gradient of the sample manager were set to achieve optimal separation between the various chromatographic peaks detected;
[0022] (5) Liquid chromatography-mass spectrometry (LC-MS) analysis
[0023] According to the LC-UV quantitative results, 13 C-labeled mixed samples were used as unified internal standard reference samples, so that each 12 C-labeled samples were mixed with the samples in equimolar amounts, and the final volume and final concentration of each test sample were set to be the same; the test samples were randomly arranged and loaded onto the machine;
[0024] (6) Data processing and screening of differential metabolites
[0025] The raw data generated by the LC-MS run were preprocessed using R-based-IsoMS software to obtain a matrix table containing retention time, mass-to-charge ratio, and peak intensity ratio;
[0026] The matrix table was imported into SIMCA 14.1 software and Metaboanalyst metabolomics online analysis platform for multivariate statistical analysis. Metabolic data were analyzed by principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). Differential metabolites were screened by metabolite difference fold analysis. Metabolites were identified based on the DNS-dansyl standard database and the MycompoundID database.
[0027] Furthermore, biomarkers related to the effectiveness of mesenchymal stem cells in treating Crohn's disease mice were screened out, and the receiver operating characteristic (ROC) curve was drawn using Graphpad 9.0 software, and the area under the curve (AUC) of the marker was calculated to evaluate the diagnostic efficacy of the biomarker.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The present invention provides the use of serum markers in the preparation of products for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease, wherein the serum markers include 4-guanidine aldehyde, β-D-pyranoglucopyranose acid and prolyl arginine isomer 1; the present invention is based on the method of isotope-labeled liquid chromatography-mass spectrometry to evaluate the changes in serum metabolites of mice with Crohn's disease treated with mesenchymal stem cells. By adopting new technical means to successfully extract serum metabolites and detect the changes in serum metabolites before and after the treatment of SAMP1 / Yit mice with placenta-derived mesenchymal stem cells, serum metabolites related to the effectiveness of mesenchymal stem cells in treating Crohn's disease are screened out and their value is evaluated, providing data support for the clinical transformation of mesenchymal stem cells in treating Crohn's disease.
[0030] The present invention screens serum differential metabolites related to the effectiveness of mesenchymal stem cell treatment of Crohn's disease from the perspective of metabolomics, provides new potential markers for the effectiveness evaluation of mesenchymal stem cell transplantation in the treatment of Crohn's disease, and helps to deeply understand the metabolic changes of Crohn's disease and the impact of mesenchymal stem cell treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is the PCA score plot of serum metabolic profile analysis.
[0032] Figure 2 OPLS-DA 3D score diagrams of the model group and the treatment group, and the model group and the control group, where (a) is the model group and the treatment group, and (b) is the model group and the control group.
[0033] Figure 3 The scatter plots show the concentration changes of three differential metabolites in different groups, among which (a) is Isomer 1 of Prolyl-Arginine: prolyl arginine isomer 1; (b) is Beta-D-Glucopyranuronic acid: β-D-pyranogluconic acid; and (c) is 4-Guanidinobutanal: 4-guanidine aldehyde.
[0034] Figure 4 This is the ROC curve of 4-guanidine.
[0035] Figure 5 This is the ROC curve of β-D-pyranoglucopyranoside.
[0036] Figure 6 This is the ROC curve of prolylarginine isomer 1.
[0037] Figure 7 The combined ROC curve of the three differential metabolites. DETAILED DESCRIPTION
[0038] The present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0039] First of all, it should be noted that the placenta-derived mesenchymal stem cells used in the present invention are derived from the sample bank of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases of the First Affiliated Hospital of Zhejiang University. The present invention does not involve the operation of removing or resecting placental tissue.
[0040] The technical solution of the present invention is described in detail below in conjunction with specific embodiments:
[0041] (I) Mesenchymal stem cell transplantation for the treatment of Crohn's disease mice:
[0042] Ten 24-week-old female SAMP1 / Yit mice were injected intraperitoneally with 200 μL PBS as the model group, and 20 mice were injected intraperitoneally with 2×10 6 MSCs / 200 μL PBS was used as the treatment group, and 10 AKR / J mice of the same age were intraperitoneally injected with 200 μL PBS as the normal control group and observed for 2 weeks;
[0043] On the 0th, 3rd, 7th, and 14th days of the experiment, 300 μL of peripheral blood was collected from the mice through the orbital venous plexus, allowed to stand at room temperature for 1 hour, and then centrifuged at 3500 rpm for 15 minutes at 4°C to obtain serum for later use;
[0044] (II) Serum metabolomics analysis
[0045] (1) Serum metabolite extraction
[0046] The serum was divided into two parts, 30 μL of one part was taken as an independent sample, 90 μL of methanol was added, the mixture was vortexed for 30 seconds to mix, and the mixture was placed in a -80°C environment for reaction for 30 minutes; 10 μL of serum was taken from the other part, mixed as a mixed sample, and the corresponding volume of methanol was added according to the ratio of serum: methanol = 1:3 (volume ratio, v / v), the solution was vortexed for 30 seconds to mix, and then placed in a -80°C environment for reaction for 30 minutes; after the reaction, the solution was centrifuged at 15,000 rpm at 4°C for 30 minutes, and the supernatant was collected; the supernatant was freeze-dried in a freeze dryer to obtain a freeze-dried sample containing serum metabolites.
[0047] (2) 12 C / 13 C-isotope labeled metabolites
[0048] Take out the freeze-dried sample, add 25 μL of pure water to resuspend, add 12.5 μL of sodium carbonate / sodium bicarbonate buffer to the resuspended sample solution, vortex mix; then add 37.5 μL of acetonitrile and dansyl marker mixed solution, vortex mix, and put the reaction system in an oven at 40°C for 45 minutes. 12C-dansyl marker was used to label independent samples. 13 C-dansyl marker was used to label the mixed sample; after the incubation, the sample was taken out of the oven and cooled to room temperature, 7.5 μL of sodium hydroxide was added, and then placed in an oven at 40°C for 10 minutes, and finally 30 μL of 5% formic acid / water solution was added to neutralize the reaction;
[0049] (3) Liquid chromatography-ultraviolet spectroscopy (LC-UV) quantification
[0050] In this experiment, an ultra-high performance liquid chromatograph equipped with a photodiode array detector and a 338 nm ultraviolet detector was used, and the chromatographic column used was an ACQUITY UPLC BEH C18 reversed-phase column (2.1 mm × 5 cm, particle size: 1.7 μm; pore size: ), set the liquid chromatography conditions as follows:
[0051] Sample manager temperature: 4°C;
[0052] Injection volume: 1 μL;
[0053] Flow rate: 500 μL / min;
[0054] Composition of mobile phase:
[0055] Mobile phase A: formic acid / water (0.1:99.9, v / v);
[0056] Mobile phase B: formic acid / acetonitrile (0.1:99.9, v / v);
[0057] Gradient elution program:
[0058] The initial setting is 95% A, 5% B, which is maintained for 1 minute and then changed to 2% A, 98% B within 0.01 minute; after maintaining for 1 minute, it is changed to 95% A, 5% B within 30 seconds and maintained for 3.5 minutes.
[0059] (4) Liquid chromatography-mass spectrometry (LC-MS) analysis
[0060] According to the LC-UV quantitative results, take 10 μL 13 C-labeled mixed samples were used as unified internal standard reference samples, and each 12 The C-labeled samples were mixed with the samples in equal molar amounts. After mixing, the total molar concentration was set to 0.49 mmol / L, and the final volume of each sample was 25 μL.
[0061] The samples were analyzed by LC-MS using an UltiMate 3000 UHPLC coupled to an Impact II quadrupole time-of-flight mass spectrometer. All MS spectra were acquired in positive ion mode at a spectral acquisition rate of 1 Hz. The liquid chromatography conditions were set as follows:
[0062] Flow rate: 400 μL / min
[0063] Composition of mobile phase:
[0064] Mobile phase A: formic acid / water (0.1:99.9, v / v);
[0065] Mobile phase B: formic acid / acetonitrile (0.1:99.9, v / v);
[0066] Gradient elution program:
[0067] The initial setting was 75% A and 25% B, changed to 1% A and 99% B after 10 minutes, maintained for 3 minutes, changed to 75% A and 25% B, and maintained for 3 minutes.
[0068] Before testing the samples, repeat the quality control samples for at least 5 times to examine the stability of LC-MS chromatographic peak separation and mass spectrometry signal response; during the test, a blank sample and a 12 C-labeled mixed amino acid standard sample and a quality control sample were repeated alternately;
[0069] (5) Data analysis and processing and screening of differential metabolites
[0070] In this example, a total of 1842 peak pairs were detected. The raw data generated by the LC-MS run were preprocessed using R-based-IsoMS software. After peak collection, peak pairing, peak filtering, and using a zero-fill program to replace missing values, IsoMS-Quant determined 12 C- / 13 C-peak intensity ratio, a three-dimensional matrix table including retention time, mass-to-charge ratio and peak intensity ratio was obtained; the relative molecular mass of the metabolite was obtained according to the accurate mass-to-charge ratio, combined with the retention time, and matched with the DNS-standard database and the MycompoundID database. In this example, a total of 1369 metabolites were determined.
[0071] The matrix table was imported into SIMCA 14.1 software and Metaboanalyst metabolomics online analysis platform for multivariate statistical analysis, and PCA analysis was performed on all sample data including QC samples ( Figure 1 ), and then perform OPLS-DA analysis on the data between different groups ( Figure 2), to obtain the overall trend of changes and verify the reliability of LC-MS detection; set the difference multiple>1.2 and P<0.05 to draw and screen the differential metabolites, and match them in the database to obtain 66 differential metabolites between the treatment group and the model group; after eliminating the differential metabolites unrelated to the treatment, 3 differential metabolites related to mesenchymal stem cell treatment were obtained, including 4-guanidine aldehyde, β-D-pyranogluconate, prolyl arginine isomer 1( Figure 3 );
[0072] The ROC curve was used to analyze the test efficiency of metabolite concentration changes for the diagnosis of Crohn's disease. The analysis showed that the ROC curve AUC value of 4-guanidine was 0.8000 ( Figure 4 ), the ROC curve AUC value of β-D-pyranoglucopyranose acid was 0.8263 ( Figure 5 ), the ROC curve AUC value of prolyl arginine isomer 1 was 0.8105 ( Figure 6 ).
[0073] The joint dataset of three metabolites was randomly divided into separate training and test sets (75% for training and 25% for testing), and classified using leave-one-out cross-validation. Seven supervised learning classifiers were studied on the joint dataset, including AdaBoost, kNN, logistic regression, naive Bayes, neural network, random forest, and SVM, and the results are shown in Table 1. After combining the AUC value and relevant indicators such as accuracy, F1 score, precision, and recall, the naive Bayes model was selected, and the joint AUC value obtained was 0.9429.
[0074] ( Figure 7 )
[0075] Table 1 Parameters of seven different machine learning models used in the joint dataset
[0076]
[0077] The above results indicate that the metabolites provided by the present invention have good value in evaluating the effectiveness of mesenchymal stem cells in treating Crohn's disease.
Claims
1. The use of serum markers in the preparation of a product for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease, characterized in that: The serum marker is a composition consisting of at least 4-guanidine aldehyde, β-D-pyranoglucopyranose acid and prolyl arginine isomer 1; the chemical formula of the prolyl arginine isomer 1 is shown below:
2. The use according to claim 1, characterized in that: The product includes a test kit, a chip or a test paper.
3. The use according to claim 2, characterized in that: The kit uses serum as a test sample.
4. The use according to claim 2, characterized in that: The chip comprises a solid phase carrier and probes attached thereto for specifically recognizing kynurenine and formyl-5-hydroxykynurenamine.
5. A kit for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease, characterized in that: The kit comprises reagents for detecting 4-guanidine aldehyde, β-D-pyranoglucopyranose acid and prolyl arginine isomer 1.
6. Use of a reagent for detecting serum markers in the preparation of a product for evaluating the therapeutic effect of mesenchymal stem cells on Crohn's disease, characterized in that: The serum marker adopts a composition consisting of at least 4-guanidine aldehyde, β-D-pyranoglucopyranose acid and prolyl arginine isomer 1.
7. The use according to claim 6, characterized in that: The product includes a test kit, a chip or a test paper.
